OBJECTIVE: Endothelins (ETs) are involved in several inflammatory events. The present study investigated the efficacy of bosentan, a dual ETA/ETB receptor antagonist, in collagen-induced arthritis (CIA) in mice. TREATMENT: CIA was induced in DBA/1J mice. Arthritic mice were treated with bosentan (100 mg/kg) once a day, starting from the day when arthritis was clinically detectable. METHODS: CIA progression was assessed by measurements of visual clinical score, paw swelling and hypernociception. Histological changes, neutrophil infiltration and pro-inflammatory cytokines were evaluated in the joints. Gene expression in the lymph nodes of arthritic mice was evaluated by microarray technology. PreproET-1 mRNA expression in the lymph nodes of mice and in peripheral blood mononuclear cells (PBMCs) was evaluated by real-time PCR. The differences were evaluated by one-way ANOVA or Student's t test. RESULTS: Oral treatment with bosentan markedly ameliorated the clinical aspects of CIA (visual clinical score, paw swelling and hyperalgesia). Bosentan treatment also reduced joint damage, leukocyte infiltration and pro-inflammatory cytokine levels (IL-1β, TNFα and IL-17) in the joint tissues. Changes in gene expression in the lymph nodes of arthritic mice returned to the levels of the control mice after bosentan treatment. PreproET mRNA expression increased in PBMCs from rheumatoid arthritis (RA) patients but returned to basal level in PBMCs from patients under anti-TNF therapy. In-vitro treatment of PBMCs with TNFα upregulated ET system genes. CONCLUSION: These findings indicate that ET receptor antagonists, such as bosentan, might be useful in controlling RA. Moreover, it seems that ET mediation of arthritis is triggered by TNFα.
OBJECTIVE: Endothelins (ETs) are involved in several inflammatory events. The present study investigated the efficacy of bosentan, a dual ETA/ETB receptor antagonist, in collagen-induced arthritis (CIA) in mice. TREATMENT: CIA was induced in DBA/1J mice. Arthritic mice were treated with bosentan (100 mg/kg) once a day, starting from the day when arthritis was clinically detectable. METHODS: CIA progression was assessed by measurements of visual clinical score, paw swelling and hypernociception. Histological changes, neutrophil infiltration and pro-inflammatory cytokines were evaluated in the joints. Gene expression in the lymph nodes of arthritic mice was evaluated by microarray technology. PreproET-1 mRNA expression in the lymph nodes of mice and in peripheral blood mononuclear cells (PBMCs) was evaluated by real-time PCR. The differences were evaluated by one-way ANOVA or Student's t test. RESULTS: Oral treatment with bosentan markedly ameliorated the clinical aspects of CIA (visual clinical score, paw swelling and hyperalgesia). Bosentan treatment also reduced joint damage, leukocyte infiltration and pro-inflammatory cytokine levels (IL-1β, TNFα and IL-17) in the joint tissues. Changes in gene expression in the lymph nodes of arthritic mice returned to the levels of the control mice after bosentan treatment. PreproET mRNA expression increased in PBMCs from rheumatoid arthritis (RA) patients but returned to basal level in PBMCs from patients under anti-TNF therapy. In-vitro treatment of PBMCs with TNFα upregulated ET system genes. CONCLUSION: These findings indicate that ET receptor antagonists, such as bosentan, might be useful in controlling RA. Moreover, it seems that ET mediation of arthritis is triggered by TNFα.
Authors: Ganwei Lu; Bratislav M Janjic; Jelena Janjic; Theresa L Whiteside; Walter J Storkus; Nikola L Vujanovic Journal: J Immunol Date: 2002-02-15 Impact factor: 5.422
Authors: Bernard P Leung; Naveed Sattar; Anne Crilly; Morag Prach; David W McCarey; Helen Payne; Rajan Madhok; Carol Campbell; J Alastair Gracie; Foo Y Liew; Iain B McInnes Journal: J Immunol Date: 2003-02-01 Impact factor: 5.422
Authors: Waldiceu A Verri; Thiago M Cunha; Danilo A Magro; Ana T G Guerrero; Silvio M Vieira; Vanessa Carregaro; Guilherme R Souza; Maria das Graças M O Henriques; Sérgio H Ferreira; Fernando Q Cunha Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2008-10-15 Impact factor: 3.000
Authors: Vanessa Carregaro; José M Ribeiro; Jesus G Valenzuela; Djalma L Souza-Júnior; Diego L Costa; Carlo J F Oliveira; Laís A Sacramento; Manuela S L Nascimento; Cristiane M Milanezi; Fernando Q Cunha; João S Silva Journal: PLoS Negl Trop Dis Date: 2015-04-07
Authors: Allan J C Bussmann; Sergio M Borghi; Tiago H Zaninelli; Telma S Dos Santos; Carla F S Guazelli; Victor Fattori; Talita P Domiciano; Felipe A Pinho-Ribeiro; Kenji W Ruiz-Miyazawa; Antonio M B Casella; Josiane A Vignoli; Doumit Camilios-Neto; Rubia Casagrande; Waldiceu A Verri Journal: Inflammopharmacology Date: 2019-01-05 Impact factor: 4.473
Authors: Karla G G Serafim; Suelen A Navarro; Ana C Zarpelon; Felipe A Pinho-Ribeiro; Victor Fattori; Thiago M Cunha; Jose C Alves-Filho; Fernando Q Cunha; Rubia Casagrande; Waldiceu A Verri Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2015-08-06 Impact factor: 3.000
Authors: Ga-Yeon Son; Eun-Jung Bak; Ji-Hye Kim; Dong Eun Lee; Si-Mook Kang; So Yun Lee; Lin Choi; Ji Su Sun; Seul Ki Kim; Wonse Park; Baek Il Kim; Yun-Jung Yoo; Inik Chang; Dong Min Shin Journal: PLoS One Date: 2016-12-28 Impact factor: 3.240
Authors: Fernando P Conte; Fausto K Ferraris; Thadeu E M M Costa; Patricia Pacheco; Leonardo N Seito; Waldiceu A Verri; Fernando Q Cunha; Carmen Penido; Maria G Henriques Journal: Molecules Date: 2015-02-03 Impact factor: 4.411